SAB生物治疗公司在2025年EASD会议上展示了SAB-142的I期数据，显示健康志愿者中淋巴细胞暂时下降SAB Biotherapeutics Presents Phase：Data on SAB-142 Showing Transient Lymphocyte Declines in Healthy Volunteers at 2025 EASD Conference

动脉网09-18

by Mark Chiang马克·蒋Share To分享到At the 2025 European Association for the Study of Diabetes (EASD) conference in Vienna, SAB Biotherapeutics unveiled Phase I clinical trial data for SAB-142, a fully human...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2568236951?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-09-18 17:03","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2568236951","market":"us","top_or_hot":-1,"title":"SAB生物治疗公司在2025年EASD会议上展示了SAB-142的I期数据，显示健康志愿者中淋巴细胞暂时下降SAB Biotherapeutics Presents Phase：Data on SAB-142 Showing Transient Lymphocyte Declines in Healthy Volunteers at 2025 EASD Conference","media":"动脉网","content":"<div>\n<p>by Mark Chiang马克·蒋Share To分享到At the 2025 European Association for the Study of Diabetes (EASD) conference in Vienna, SAB Biotherapeutics unveiled Phase I clinical trial data for SAB-142, a fully human...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250918170848979aaeee&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SAB生物治疗公司在2025年EASD会议上展示了SAB-142的I期数据，显示健康志愿者中淋巴细胞暂时下降SAB Biotherapeutics Presents Phase：Data on SAB-142 Showing Transient Lymphocyte Declines in Healthy Volunteers at 2025 EASD Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSAB生物治疗公司在2025年EASD会议上展示了SAB-142的I期数据，显示健康志愿者中淋巴细胞暂时下降SAB Biotherapeutics Presents Phase：Data on SAB-142 Showing Transient Lymphocyte Declines in Healthy Volunteers at 2025 EASD Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-18 17:03 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250918170848979aaeee&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>by Mark Chiang马克·蒋Share To分享到At the 2025 European Association for the Study of Diabetes (EASD) conference in Vienna, SAB Biotherapeutics unveiled Phase I clinical trial data for SAB-142, a fully human...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250918170848979aaeee&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4551","symbol_name":"寇图资本持仓","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250918170848979aaeee&s=b","article_id":"2568236951","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250918170848979aaeee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2568236951","pubTimestamp":1758186180,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"The Phase I trial results indicate that SAB-142 may offer a novel approach to modulating immune responses associated with T1D. Researchers observed that while lymphocyte levels temporarily decreased following administration of the therapy, they returned to baseline without prolonged suppression. This outcome is considered significant as it suggests that SAB-142 could be administered repeatedly without compromising long-term immune function.一期试验结果表明，SAB-142可能为调节与1型糖尿病相关的免疫反应提供一种新方法。研究人员观察到，尽管在治疗后淋巴细胞水平暂时下降，但随后恢复至基线水平，并未出现长期抑制。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4551":"寇图资本持仓","BK4587":"ChatGPT概念","BK4588":"碎股","BK4528":"SaaS概念","BK4023":"应用软件","BK4585":"ETF&股票定投概念","SABS":"SAB Biotherapeutics, Inc.","BK4139":"生物科技","BK4543":"AI"},"translate_title":"SAB Biotherapeutics Presents Phase I Data for SAB-142 at EASD 2025, Showing a Temporary Decline in Lymphocytes in Healthy Volunteers SAB Biotherapeutics Presents Phase: Data on SAB-142 Showing Transient Lymphocyte Declines in Healthy Volunteers at 2025 EASD Conference","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SABS":0.9},"content_text":"by Mark Chiang马克·蒋Share To分享到At the 2025 European Association for the Study of Diabetes (EASD) conference in Vienna, SAB Biotherapeutics unveiled Phase I clinical trial data for SAB-142, a fully human, multi-specific anti-thymocyte globulin (ATG). The investigational therapy is designed to address autoimmunity in type 1 diabetes (T1D).在2025年维也纳欧洲糖尿病研究协会（EASD）会议上，SAB Biotherapeutics公布了SAB-142的I期临床试验数据，这是一种全人源、多特异性的抗胸腺细胞球蛋白（ATG）。该研究性疗法旨在解决1型糖尿病（T1D）中的自身免疫问题。The randomized, placebo-controlled study, conducted on healthy volunteers, demonstrated transient declines in lymphocyte levels without causing sustained depletion. These findings support advancing the therapy into the Phase IIb SAFEGUARD trial and suggest potential for repeat dosing aimed at modifying disease progression in newly diagnosed stage 3 T1D patients..这项针对健康志愿者开展的随机、安慰剂对照研究显示，淋巴细胞水平出现短暂下降，但并未导致持续耗竭。这些发现支持将该疗法推进到 IIb 期 SAFEGUARD 试验，并表明有望通过重复给药来改变新诊断的 3 期 T1D 患者的疾病进展。The Phase I trial results indicate that SAB-142 may offer a novel approach to modulating immune responses associated with T1D. Researchers observed that while lymphocyte levels temporarily decreased following administration of the therapy, they returned to baseline without prolonged suppression. This outcome is considered significant as it suggests that SAB-142 could be administered repeatedly without compromising long-term immune function.一期试验结果表明，SAB-142可能为调节与1型糖尿病相关的免疫反应提供一种新方法。研究人员观察到，尽管在治疗后淋巴细胞水平暂时下降，但随后恢复至基线水平，并未出现长期抑制。这一结果被认为具有重要意义，因为它表明SAB-142可以反复给药而不会损害长期免疫功能。The upcoming Phase IIb SAFEGUARD trial will further evaluate the safety and efficacy of this treatment in individuals recently diagnosed with stage 3 T1D..即将进行的第二阶段SAFEGUARD试验将进一步评估这种治疗在近期被诊断为3期T1D患者中的安全性和有效性。Newsflash | Powered by GeneOnline AI新闻快讯 | 由GeneOnline AI提供支持Source: GO-AI-ne1来源：GO-AI-ne1For any suggestion and feedback, please contact us.如果有任何建议和反馈，请联系我们。Date: September 18, 2025日期：2025年9月18日Related posts:相关内容：AI and 3D Printing Reshape Generic Drug Development, Accelerating Market Entry人工智能和3D打印重塑仿制药开发，加速市场进入Calley Means Contributes to Presidential Commission Report on Chronic Diseases in Children卡利·米恩斯为总统委员会关于儿童慢性病的报告做出了贡献。Evolving US Policies and Vertical Integration Drive Early Market Access Planning for Affordable Therapies不断发展的美国政策和垂直整合推动了可负担疗法的早期市场准入规划Wellvana Saves Medicare $327 Million While Excelling in MSSP Quality MetricsWellvana在MSSP质量指标上表现出色，同时为Medicare节省了3.27亿美元©www.geneonline.com All rights reserved. Collaborate with us:©www.geneonline.com 保留所有权利。与我们合作：[email protected]电子邮件地址Author作者Mark Chiang马克·江Related Post相关文章Technology技术Japan’s EdgeCortix Bets on Space to Challenge Nvidia’s Grip on AI Chips日本的EdgeCortix押注太空以挑战英伟达在AI芯片领域的主导地位2025-09-182025年9月18日","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2568236951","isCrawlerRequest":true}